Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition

Stefan Buchholz; Stephan Seitz; Andrew V. Schally; Jörg B. Engel; Ferenc G. Rick; Luca Szalontay; Florian Hohla; Awtar Krishan; Andrea Papadia; Timo Gaiser; Gero Brockhoff; Olaf Ortmann; Klaus Diedrich; Frank Köster

doi:10.3892/ijo-00000391

Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition

Stefan Buchholz, Stephan Seitz, Andrew V. Schally, Jörg B. Engel, Ferenc G. Rick, Luca Szalontay, Florian Hohla, Awtar Krishan, Andrea Papadia, Timo Gaiser, Gero Brockhoff, Olaf Ortmann, Klaus Diedrich, Frank Köster^*

^*Corresponding author for this work

Clinic of Gynecology and Obstetrics

31 Citations (Scopus)

Abstract

The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist Cetrorelix. Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. The proliferation of both TNBC cell lines was significantly inhibited in vitro by 1 μM Cetrorelix. Injections of 3 mg Cetrorelix on day 1 and 21 resulted in a significant growth inhibition of HCC1806 tumors xenografted into nude mice. Tumors of mice treated with Cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. After treatment of cells with Cetrorelix a flow cytometric analysis of the cell cycle revealed a decrease in S-phase. Given the low toxicity and clinical availability of Cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC.

Original language	English
Journal	International Journal of Oncology
Volume	35
Issue number	4
Pages (from-to)	789-796
Number of pages	8
ISSN	1019-6439
DOIs	https://doi.org/10.3892/ijo-00000391
Publication status	Published - 01.10.2009

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/ijo-00000391

Cite this

Buchholz, S., Seitz, S., Schally, A. V., Engel, J. B., Rick, F. G., Szalontay, L., Hohla, F., Krishan, A., Papadia, A., Gaiser, T., Brockhoff, G., Ortmann, O., Diedrich, K., & Köster, F. (2009). Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. International Journal of Oncology, 35(4), 789-796. https://doi.org/10.3892/ijo-00000391

@article{f77cc793fbb047718966c0acefe1d3f9,

title = "Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition",

abstract = "The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist Cetrorelix. Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. The proliferation of both TNBC cell lines was significantly inhibited in vitro by 1 μM Cetrorelix. Injections of 3 mg Cetrorelix on day 1 and 21 resulted in a significant growth inhibition of HCC1806 tumors xenografted into nude mice. Tumors of mice treated with Cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. After treatment of cells with Cetrorelix a flow cytometric analysis of the cell cycle revealed a decrease in S-phase. Given the low toxicity and clinical availability of Cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC.",

author = "Stefan Buchholz and Stephan Seitz and Schally, {Andrew V.} and Engel, {J{\"o}rg B.} and Rick, {Ferenc G.} and Luca Szalontay and Florian Hohla and Awtar Krishan and Andrea Papadia and Timo Gaiser and Gero Brockhoff and Olaf Ortmann and Klaus Diedrich and Frank K{\"o}ster",

year = "2009",

month = oct,

day = "1",

doi = "10.3892/ijo-00000391",

language = "English",

volume = "35",

pages = "789--796",

journal = "International Journal of Oncology",

issn = "1019-6439",

number = "4",

}

Buchholz, S, Seitz, S, Schally, AV, Engel, JB, Rick, FG, Szalontay, L, Hohla, F, Krishan, A, Papadia, A, Gaiser, T, Brockhoff, G, Ortmann, O, Diedrich, K & Köster, F 2009, 'Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition', International Journal of Oncology, vol. 35, no. 4, pp. 789-796. https://doi.org/10.3892/ijo-00000391

Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. / Buchholz, Stefan; Seitz, Stephan; Schally, Andrew V. et al.
In: International Journal of Oncology, Vol. 35, No. 4, 01.10.2009, p. 789-796.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition

AU - Buchholz, Stefan

AU - Seitz, Stephan

AU - Schally, Andrew V.

AU - Engel, Jörg B.

AU - Rick, Ferenc G.

AU - Szalontay, Luca

AU - Hohla, Florian

AU - Krishan, Awtar

AU - Papadia, Andrea

AU - Gaiser, Timo

AU - Brockhoff, Gero

AU - Ortmann, Olaf

AU - Diedrich, Klaus

AU - Köster, Frank

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist Cetrorelix. Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. The proliferation of both TNBC cell lines was significantly inhibited in vitro by 1 μM Cetrorelix. Injections of 3 mg Cetrorelix on day 1 and 21 resulted in a significant growth inhibition of HCC1806 tumors xenografted into nude mice. Tumors of mice treated with Cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. After treatment of cells with Cetrorelix a flow cytometric analysis of the cell cycle revealed a decrease in S-phase. Given the low toxicity and clinical availability of Cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC.

AB - The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist Cetrorelix. Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. The proliferation of both TNBC cell lines was significantly inhibited in vitro by 1 μM Cetrorelix. Injections of 3 mg Cetrorelix on day 1 and 21 resulted in a significant growth inhibition of HCC1806 tumors xenografted into nude mice. Tumors of mice treated with Cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. After treatment of cells with Cetrorelix a flow cytometric analysis of the cell cycle revealed a decrease in S-phase. Given the low toxicity and clinical availability of Cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC.

UR - http://www.scopus.com/inward/record.url?scp=70449359173&partnerID=8YFLogxK

U2 - 10.3892/ijo-00000391

DO - 10.3892/ijo-00000391

M3 - Journal articles

C2 - 19724914

AN - SCOPUS:70449359173

SN - 1019-6439

VL - 35

SP - 789

EP - 796

JO - International Journal of Oncology

JF - International Journal of Oncology

IS - 4

ER -

Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this